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ABSTRACT
Background 
There is an urgent clinical need for an alternative vascular graft, especially for smaller artery 
applications such as in below-knee and coronary artery bypass.  Currently available synthetic grafts 
have unacceptably low patency rates, while autologous saphenous vein grafts are not feasible in one 
third of patients.
Decellularised vascular grafts have been investigated as alternative conduits, but this chemical 
treatment results in degradation of the extracellular matrix.  Chemical stabilization of elastin with 
penta-galloyl glucose (PGG) combined with collagen stabilisation during covalent heparinisation was 
previously investigated by our group in a small animal model and shown to be effective and safe.  The 
current study describes their evaluation in a large animal (ovine) model. 
Methods 
Porcine mammary arteries were harvested, decellularised according to an established protocol 
involving rinsing with sodium hydroxide, alcohol (ETOH), treatment with DNAse/RNAse enzymes, 
immersion in PGG and subsequently surface modified with covalently bound heparin. Samples of the 
grafts were also tested for radial and suture retention strength. 
The prepared grafts were implanted as interposition grafts into the carotid arteries of 6 sheep, using 
industry standard 6mm expanded polytetrafluoroethylene (ePTFE) on the contralateral side of each 
animal as control.  In-situ patency was determined by ultrasound and angiography at two months, 
following which the grafts were explanted for macro- and microscopic analysis.  
Results 
In-vitro evaluation: Grafts showed significant levels of bound heparin (14.56 mg/g vs 0.69mg/g in 
untreated tissue) and demonstrated similar mechanical properties to those of human carotid arteries. 
Survival: Five out of six sheep survived the full 2-month implant period, while the remaining animal 
developed sepsis shortly after implantation and was euthanized on day 4. 
Patency: None of the decellularised grafts were patent at explant, as assessed by ultrasound, 
angiography and macroscopic examination.  Two of the five control (ePTFE) grafts were patent. 
Microscopic analysis: An inflammatory cell infiltrate with vascularised granulation tissue was found 
encasing the decellularised xenografts with little or no sign of endothelial cell infiltration.  Signs of 
early occlusion, likely due to technical factors, was noted at the sites of anastomosis. 
Conclusion 
Although demonstrating similar mechanical properties to human carotid arteries, and promising 
results in the small animal model, the stabilised decellularised vascular grafts failed to achieve 
endothelialisation or patency in this sheep carotid model.  Significant calibre mismatch between the 
test graft and the native artery is thought to be the primary factor in the failure of these grafts, 
highlighting the potential difficulty in acquiring grafts of an appropriate size from animal sources. 
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1. INTRODUCTION 
The morbidity and mortality associated with the various manifestations of cardiovascular disease 
(CVD) viz. cerebrovascular, coronary artery and peripheral arterial disease, and the complications that 
result from their surgical management cause profound suffering for many patients and is a major 
burden on health care systems worldwide. Peripheral arterial disease (PAD) has an overall prevalence 
of 3-10% and is present in 20% of people over 70 years of age.1 Loss of limbs to amputations is a 
frequent occurrence in these patients, resulting in profound lifestyle-limiting disability. 
1.1. Epidemiology of cardiovascular disease (CVD) 
Epidemiological data for sub-Saharan Africa is not as clearly defined due to a lack of reliable health 
records. As more African communities adopt a westernized lifestyle, the prevalence of CVD risk factors 
continues to increase.   A review of the available health statistics in sub-Saharan Africa showed that, 
although the incidence of CAD is under-reported, the rising prevalence of CVD risk factors including 
hypertension, obesity, physical inactivity and tobacco use, predicts an exponential increase in the 
incidence of CAD.  The true impact of CVD is also overshadowed by the large burden of infectious and 
trauma-related deaths.2 The Global Burden of Diseases (GBD) study showed that, although the relative 
prevalence of these diseases is smaller than in Europe and America, the absolute rates have increased 
dramatically between 1990 and 2010.  Furthermore, the prevalence of PAD was greater among adults 
younger than 55 years old.  This contrasts with the pattern in the first world and is further cause for 
concern as the disease affects adults in their productive years of life.3 
1.2. Current surgical management of PAD 
The basis of surgical management of PAD is a bypass procedure with either autologous vein or 
synthetic vascular grafts.  Although advancements in tissue engineering technologies have provided 
alternative conduits for revascularization procedures, autologous vein remains the superior conduit.  
In a meta-analysis of randomized trials comparing autologous vein grafts to polytetrafluoroethylene 
(PTFE) in above-knee bypasses, 80% of venous bypasses remained patent at 2 years compared to 69% 
of PTFE bypasses.  At five years, the patency rates dropped to 74% and 39% respectively, 
demonstrating the superior durability of vein grafts over synthetic grafts.4 Similarly, whereas sepsis of 
vein grafts is rare, infection rates of synthetic grafts occur in up to 5% of patients.5   
In below-knee bypass, the patency rate of synthetic grafts differs even more significantly from 
autologous vein.  In their multicentre randomized trial comparing autologous vein to ePTFE  for below-
knee bypasses, Veith et al reported a patency rate of ePTFE  at four years of 12% compared to 49% in 
autologous vein bypasses for the same implant period .6  
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1.3. Strategies to improve patency of synthetic grafts 
In an attempt to improve the patency of synthetic grafts, various modifications to the graft material 
and surgical technique have been developed.  These include vein cuffing (where a short segment of 
autologous vein is interposed between the graft and native vessel), heparin bonding and the creation 
of arterio-venous fistulae.  Heparin bonding appears to increase the 1-year patency rate,7 but this 
benefit is lost beyond 2 years.8  Similarly, vein-cuffing improves primary patency rates but this does 
not reduce the risk of limb loss within 3 years.9  More recent data shows that these synthetic graft 
modifications have conferred little benefit.  In their review of the last 20 years of study into below-
knee bypasses, Ziegler et al (2012) reported an average primary patency rate of 24% for ePTFE 
incorporating these modifications, compared to 69% of autologous vein grafts.10   
 
Although the saphenous vein is most often used in these clinical situations, it is unsuitable in up to 
one third of patients due to small size, varicosities or anatomic variation.11  Despite extensive study 
into tissue engineering and surgical techniques, the patency rate of synthetic grafts in below-knee 
bypass is still unacceptably low. There is thus still an urgent need for a suitable alternative vascular 
conduit, especially for smaller artery applications such as in below-knee bypass.  Drawing on work 
done in vascular dynamics, haematological physiology and tissue engineering, the factors which 
determine graft success have come to be increasingly understood. Strategies for mitigating or 
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2. FACTORS WHICH DETERMINE GRAFT PATENCY 
Synthetic vascular grafts perturb vascular physiology in two primary ways, often leading to graft 
occlusion.  First, as it lacks an endothelial lining, the synthetic material of the luminal surface of the 
graft is exposed to the proteins and platelets that comprise the coagulation system, resulting in clot 
formation.  Second, differing mechanical responses between native arteries and implanted grafts 
results in intimal hyperplasia, especially at sites of anastomosis.  
 
2.1. Endothelium and thrombogenicity 
The endothelium, which acts as the interface between blood and the underlying tissues, is a complex 
and highly specialized cellular barrier.  By responding to a myriad of hormones and cytokines and 
controlling the movement of platelets and inflammatory cells, it plays a central role in the regulation 
of thrombosis, inflammation, perfusion and healing.12  Recognising the importance of the endothelium 
in maintaining graft patency, much of the research into vascular grafts has examined various 
techniques for achieving luminal endothelialisation.  There are three known mechanisms of 
spontaneous in-vivo graft endothelialisation:  
• transanastomotic migration of endothelial cells (ECs) from the native vessel13 
• adherence of circulating endothelial progenitor cells (EPCs)13 
• transmural endothelialisation from capillary ingrowth through the graft wall13–15 
 
While in humans, transanastomotic endothelialisation has been shown to be limited to approximately 
1-2cm of growth,16 many animal studies have demonstrated complete endothelialisation of a variety 
of graft materials, including ePTFE and Dacron (Polyethylene terephthalate).   These apparent 
successes have, however, not translated to similar results in the clinical setting, highlighting the wide 
species variation in vascular physiology and the consequent inherent limitation of animal studies.  
 
2.2. Intimal hyperplasia and anastomotic stenosis 
Intimal hyperplasia occurs as a result of the migration of smooth muscle cells and increased 
production of cellular matrix at anastomotic sites.  The mechanisms that stimulate this cellular 
migration are incompletely understood but involve an imbalance between inhibitory and stimulatory 
paracrine signals between endothelial and smooth muscle cells, and as a result of surgical injury.17 
 
It is known that the endothelium responds to physical forces within the lumen of blood vessels.  Via 
various chemical mediators (e.g. nitric oxide), the diameter and compliance of arterial walls vary 
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dynamically in response to luminal pressure.  A low mean wall shear stress (WSS) has been shown to 
be the primary mechanical parameter affecting endothelial cell physiology and predicts the 
development of atherosclerosis.  Synthetic vascular grafts such as ePTFE and Dacron graft are more 
rigid and disrupt this normal physiology.  Size and compliance mismatch between the graft and native 
artery results in abnormal flow patterns, which leads to decreased WSS17 and abnormal stress patterns 
at the anastomotic site.  Remodelling occurs in an attempt to compensate for this mechanical 
mismatch, leading to progressive occlusion of the graft.18  The importance of these effects in 
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3. DEVELOPING THE IDEAL VASCULAR GRAFT 
Understanding the mechanisms which underlie graft failure, further work in the development of 
alternative vascular conduits has sought to mitigate these factors by simulating physiological 
conditions.  In addition to strategies to decrease luminal thrombogenicity and intimal hyperplasia, 
factors which determine safety and clinical feasibility also need to be considered.22,23   A model for the 
ideal vascular graft would thus be characterised by:  
• an endothelial-lined luminal surface or the capacity to facilitate in vivo endothelialisation  
• mechanical properties similar to that of native arteries 
• safe and non-toxic host interactions 
• favourable surgical handling properties 
• a feasible and scalable manufacturing process  
 
3.1. Tissue engineering strategies to produce the ideal vascular graft 
Combining techniques from engineering, cell biology and materials science, tissue engineering 
strategies to produce the ideal vascular graft have evolved steadily over the last 50 years. Two 
essential elements are common to most approaches: a scaffold, which provides the substrate for 
cellular infiltration, and cell seeding or infiltration of the scaffold.  
 
The scaffolds, which are utilised as a substrate for cellular infiltration, are either composed of synthetic 
materials or are derived from animal sources.  Currently investigated synthetic conduits are composed 
of biodegradable polymers similar to those used for suture materials, such as polylactic acid (PLA), 
polyglycolic acid (PGA), or poly-epsilon-caprolactone (PCL).23  Animal-derived materials are harvested 
from a variety of tissues such as blood vessels, skin, liver, intestinal mucosa, and can be harvested 
from both human or non-human sources.24  
 
Endothelialisation of these scaffolds is then achieved either in-vitro by cell-seeding in a bio-reactor 
prior to implantation, or in-vivo with infiltration of various cell populations (endothelial, fibroblasts 
and inflammatory cells) occurring after implantation within the graft recipient.  Each approach has its 
relative advantages and disadvantages, with research groups dedicated to the development of a 
particular approach working toward ameliorating the disadvantages.  For example, conduits 
composed of synthetic biodegradable materials have the potential to facilitate cell infiltration and 
remodelling and thus adapt to the needs of the host, analogous to the angiogenesis that occurs in 
juveniles.  However, as the chemical and mechanical characteristics of these materials often differ 
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significantly from native arteries, the maintenance of patency and adequate mechanical strength 
during the remodelling process is challenging.23  
 
Compared to in-vivo models, in-vitro methods of achieving endothelialisation allow more 
sophisticated preparation techniques such as flow and pressure pre-conditioning, which increase the 
probability of successful endothelial formation.  Additionally, the graft has an intact endothelium at 
the time of implantation, which could prevent early graft thrombosis and occlusion.  In their 15-year 
series of 310 patients implanted with in-vitro endothelialised ePTFE grafts of 6-7mm, Deutsch et al 
showed a patency rate of 69% at 5 years.25  However, these advantages come at a significant cost in 
terms of both time and resources, decreasing the clinical feasibility of these strategies.26  For example, 
in this same series the mean delay to implantation was 27 days.   
 
Thus, despite the successes achieved with more complex in-vitro approaches, the trend in the study 
of tissue engineering of vascular grafts has shifted toward strategies which seek to facilitate in-vivo 
endothelialisation.22  It is thought that the combination of decellularised vascular scaffolds with in-
vivo endothelialisation has the potential to harness the relative advantages while minimising the 
disadvantages of the various tissue engineering approaches.  The extracellular matrix (ECM) of 
decellularised vascular grafts possesses the three-dimensional architecture and cell-signalling proteins 
which could facilitate the migration, adhesion and proliferation of the various cell populations of each 
layer of an artery, including the endothelium.  Additionally, it is primarily the connective tissue 
framework comprised of elastin and collagen fibres present in the ECM which determines the 
mechanical properties of arteries.23    
 
3.2. Producing a decellularised graft 
Decellularised vascular scaffolds are produced by removing cellular compounds such as DNA, lipids 
and glycosylated products, which are antigenic and incite an inflammatory response and would result 
in rapid graft rejection.   The decellularisation process can, however, also remove or degrade desirable 
ECM compounds, which can alter the mechanical properties of the graft.   The goal is thus to remove 
the immunogenic compounds while maintaining the mechanical and chemical integrity of the 
ECM.24,27 
 
Decellularisation protocols used for vascular grafts originated in the advancements achieved in tissue 
engineering of other tissues such as heart valves and have continued to evolve, with various 
biochemical techniques developed and their utility validated.  Most protocols involve a combination 
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of washing with detergent and/or alkaline treatments and specific enzymes directed at cellular 
compounds (e.g. DNase, RNase, lipase and proteases).27  Using a combination of DNase and sodium 
deoxycholate (detergent) on porcine carotid arteries, Pellagata et al demonstrated that all cellular 
material was removed while maintaining the mechanical integrity of the graft.  There was no statistical 
difference in the major parameters of mechanical testing including Young’s modulus, compliance, 
ultimate stress, burst pressure and suture retention strength.  There was a significant difference in 
ultimate strain, which the authors attributed to the absence of smooth muscle cell interaction with 
ECM fibers.18  In contrast, Williams et al, applied a different decellularisation protocol and found major 
ultra-structural alterations in collagen and elastin fibres, which caused significant differences in the 
mechanical properties of decellularised vessels compared to native arteries.28  The contrast of these 
results highlights the importance of utilising a decellularisation protocol which preserves collagen and 
elastin in order to maintain the mechanical properties of naturally derived vascular grafts. 
 
3.3. Elastin stabilisation – preventing degradation and calcification  
Elastin is an important ECM protein which imparts the capacity to distend and recoil in response to 
luminal pressure. It is present to varying degrees in all layers of blood vessels depending on its location 
in the vascular tree.  For example, the tunica media of the aorta and pulmonary arteries are comprised 
of multiple layers of elastin which allows greater distensibility to receive blood directly from the heart 
and enables the elastic recoil which maintains blood flow during the diastolic phase of the cardiac 
cycle.  More peripheral arteries such as the femoral artery are predominantly muscular and have 
fewer elastin fibres, which are concentrated in two distinct layers - the internal and external elastic 
lamellae.29  
 
In contrast to other proteins present in the ECM, which are derived from multiple complex genes, the 
precursors of elastin are encoded on the single ELN gene.  Active elastin production occurs in-utero 
and during the first few years of life, after which ELN gene expression rapidly decreases.30  The inability 
to replenish elastin necessitates a stability uncharacteristic of other ECM proteins.  The turnover rate 
of elastin under normal conditions is thus very slow, with a mean half-life of 74 years.31  The clinical 
implication of this reduced turnover is that elastin damage and degradation tends to accumulate, 
causing persistent arterial disease even after the inciting pathological process has resolved.32 
 
Despite much study into the mechanisms of elastin degradation, the molecular basis of arterial 
stiffening and aneurysm formation is incompletely understood.  The pathophysiology involves a 
complex interaction of numerous factors including endothelial damage, inflammatory responses, 
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matrix metalloproteinase (MMP) activation and calcification of elastin fibres.33  Elastin is inherently 
resistant to proteolysis but is susceptible to degradation by a limited number of proteinases in the 
MMP family.34 MMP-mediated degradation, in turn, facilitates calcification of elastin fibres via 
unknown mechanisms and is thought to be the initiating event in the sequence culminating in arterial 
calcification.  Animal models have demonstrated that chemical stabilisation of elastin against MMP 
degradation effectively prevents calcification of elastin-rich tissues.35   
 
The importance of chemical stabilisation of elastin was first investigated in naturally derived cardiac 
valves35,36 and later, similar techniques applied to decellularised arteries. Simionescu et al first 
described the use of penta-galloyl-glucose (PGG), a stabilising polyphenolic tannin, to reduce the 
degradation of elastin. Using a combination of alkaline wash (Sodium hydroxide, NaOH) and PGG 
treatment of porcine carotid arteries, this group investigated various aspects of PGG stabilisation.37  
In vitro testing of the grafts demonstrated strong resistance to elastase conferred by PGG.38  In-vivo 
tests, by subdermal implantation of segments of the grafts in rats, demonstrated the infiltration of 
fibroblasts and smooth muscle cells and showed signs of early remodelling.  Finally, mechanical testing 
showed no statistical difference in overall strength and compliance compared to fresh arteries.37  PGG-
stabilised grafts were stiffer than fresh arteries at low strains but the elastic moduli approached that 
of fresh arteries at higher strains. 
 
3.4. Heparinisation and stabilisation of collagen 
Collagen is the major determinant of tensile strength in arteries and other structures such as tendons 
and bone.  In contrast to elastin, collagen metabolism is ongoing throughout life, and responds to 
several biomechanical and chemical cues. It is produced by multiple cell populations present in the 
ECM including fibroblasts and macrophages, but is also susceptible to breakdown by a wide range of 
proteases.39  
 
The bonding of heparin to decellularised vascular grafts has been found to have the added effect of 
stabilising collagen.  Passive absorption by soaking decellularised grafts in heparin solutions is not 
effective as the collagen within these grafts lack heparin binding (amine) sites.  To overcome this 
limitation, methods of covalent linkage of heparin by pre-treatment with amine groups were 
developed.40,41  Based on this earlier work, Pennel et al developed and validated such a protocol for 
heparin bonding which involves first treating the decellularised grafts with Jeffamine® (a diamine) 
followed by heparin coupling.  This method achieves significantly increased heparin content of the 
grafts compared to those which were reacted with activated heparin alone.42,43  Also, as the 
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carbodiimide activated amination of the tissue results in crosslinking of the collagen, increased 
denaturation temperatures and a 3-4 fold resistance to collagenase in grafts was demonstrated.42  
 
3.5. Combined elastin and collagen stabilisation 
Having validated elastin and heparin stabilisation separately, our group then evaluated the biological 
feasibility of combining these methods in a single protocol.  Elastin stabilisation with PGG and collagen 
stabilisation with diamine cross-linking and covalent heparinisation was applied to decellularised 
porcine renal arteries.  These stabilised decellularised grafts were implanted as interpositional grafts 
in rat abdominal aortas to compare patency rates and the degree of elastin and collagen degradation 
to untreated control grafts.  Patency rates were high in both untreated and stabilised grafts but the 
rate of aneurysm formation and degree of elastin degradation was significantly decreased in the 
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4. NEED FOR LARGE ANIMAL EXPERIMENTATION 
The rat aorta is a useful in-situ model for demonstrating biocompatibility and to assess the degree and 
nature of cell infiltration (including endothelialisation) and degradation of the graft material.  
However, it is not a robust test of graft patency as various vascular conduits have frequently 
demonstrated excessively high rates of patency in rats.13 For example, van Der Lei et al demonstrated 
100% patency for 1.5mm ePTFE and polyurethane grafts implanted in the rat aorta44 as did Pennel et 
al in testing PGG-stabilised decellularised vascular grafts.42  In contrast, when small calibre synthetic 
grafts were investigated for their use in coronary artery bypass graft (CABG) in humans, the results 
were consistently poor, with patency rates as low as 14% after 3 years.45    Large animal models are 
thus required that are more representative of human vascular physiology and flow dynamics to 
provide a more clinically relevant test of vascular grafts.   
 
4.1. Rationale for selection of ovine carotid model 
Several factors are considered in selecting an appropriate animal model for testing vascular grafts.  
Both the animal species and anatomical site of the implant are considered to most accurately simulate 
human physiology.  Secondary considerations include cost, ease of handling and response to 
anaesthesia.13  As the ultimate clinical goal is the implantation of animal-based vascular grafts into 
humans, demonstrating cross-species viability is fundamental to the study of decellularised grafts.   
 
Non-human primates simulate human physiology most accurately, but ethical concerns have 
precluded their use internationally.  Canine models were regarded as the next best model as, like 
humans, they lacked the ability to completely endothelialise synthetic grafts.46,47  However, more 
recent animal rights considerations also limited the use of canine models in animal experiments.13  
Based on all of these factors, the ovine model is most feasible and is currently utilised in most large 
animal model testing of vascular conduits. 
 
4.2. Comparative haematology 
Compared to that of the dog or pig, the coagulation system of sheep bears more similarity to human 
physiology.48 The rate of platelet activation by thrombin and platelet-activating factor is similar to 
humans but there is an increased number (3-8 x 105/mL vs 2-5 x 105 /mL) and adhesiveness of platelets 
in sheep.  This, and decreased fibrinolytic activity, mean there is a somewhat greater tendency toward 
hypercoagulability in sheep.49  There are also differences of the other constituents of blood including 
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increased red blood cell fragility and a predominant lymphocytic component of white blood cells, 
compared to a relative neutrophilia in humans.50 
 
The changes in coagulation physiology in response to anaesthesia and heparin administration have 
been shown to be similar in humans and sheep.  Tillman et al examined platelet function and 
coagulation parameters of sheep at various times during a 5-hour vascular procedure and 
demonstrated little change caused by anaesthesia and surgery, and a response to heparin comparable 
to that in humans.51 
 
In contrast, the effectiveness of anti-platelet agents such as aspirin and clopidogrel is reduced in 
sheep.  Higher doses of clopidogrel are required to achieve levels of anti-platelet activity in sheep 
which are comparable to humans,52,53 while  aspirin has minimal anti-platelet activity.53  
 
4.3. Comparative anatomy 
The ovine carotid artery is the most commonly used model for the assessment of vascular grafts 
intended for peripheral artery applications (i.e. 4-6mm diameter applications).  The ovine common 
carotid artery has sufficient length and is surgically accessible and implantation in the neck is well 
tolerated with minimal postoperative morbidity.13 
 
Anatomically, there are extensive anastomotic connections between the left and right side, and the 
anterior (carotid artery) and posterior circulation (basilar artery).  Unilateral occlusion results in 
dynamic responses in the remaining vascular beds, shunting blood to compensate for the loss of 
flow.54  Simultaneous bilateral occlusion may cause reversible cerebral ischaemia but sequential loss 
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5. REVIEW OF SHEEP CAROTID MODEL STUDIES 
A review of studies which have utilised the ovine carotid model to evaluate vascular grafts again 
highlight the importance of an intact endothelial layer in maintaining patency.  In their study 
comparing decellularised porcine arteries, which were seeded with ovine endothelial progenitor cells 
(EPC) versus the same porcine graft without seeding, Kaushal et al demonstrated 100% patency in the 
endothelialised group vs 0% in the un-seeded group.56  An intact endothelium also appears to confer 
the ability to heal from injury.  Tillman et al subjected EPC-seeded decellularised porcine grafts to 
multiple puncture over the course of several months.  The grafts remained patent for a mean of 4.4 
(± 0.9) months, which is comparable to venous grafts under similar conditions.57  Like other studies 
which have employed this method to achieve luminal endothelialisation, these promising results came 
at a significant cost.  In the Kaushal study for example, three weeks of culture time was required to 
produce sufficient EPCs.  Also, as previous work in EPCs have demonstrated that 80% of these cells 
are lost when exposed to shear stress in vivo, the seeded grafts were subjected to 4 days of pressure 
pre-conditioning in a bioreactor prior to implantation.56 
 
In contrast, studies relying on in-vivo endothelialisation have thus far yielded disappointing results.  In 
their study of 6mm diameter vascular grafts composed of hydrated small intestinal mucosa, Pavcnik 
et al, demonstrated a 30% patency rate at 3 months.58  Microscopic examination of the specimens 
from this and other studies show migration of fibroblasts and other inflammatory cell populations but 
limited endothelialisation of the luminal surface.  To facilitate the transmural migration of endothelial 
cells, physical modifications to alter the porosity of the grafts have been employed.  Bergmeister et al 
used laser perforations of decellularised grafts to increase porosity.  Compared to non-perforated 
grafts, endothelialisation was slightly improved at 6 weeks but there was no difference in the extent 
of endothelialisation at 3 months.59  Additionally, the perforated grafts developed a thicker neointima, 
which resulted in a lower patency rate in the perforated group.  
 
These attempts to achieve in-vivo endothelialisation in an ovine carotid model have not yet achieved 
results superior to PTFE grafts of comparable size which are implanted under similar conditions.  After 
6 months, 17% - 50% of 5-6mm ePTFE grafts range remain patent.60–62  This rate is also similar to the 
patency rate of PTFE in below-knee bypass in humans, making the use of PTFE in the ovine carotid 
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6. CONCLUSION  
Despite 50 years of ongoing research, there remains a need for a suitable alternative conduit for small 
and medium sized bypass applications.  The successes achieved with in-vitro endothelialisation with 
EPC culture and seeding reaffirms the pivotal role an intact endothelium plays in maintaining patency. 
However, with the time required to produce these grafts, their wide-scale application is prohibitively 
resource intensive.  In attempting to produce an ‘off-the-shelf’ vascular graft, the strategy has shifted 
toward achieving in-vivo endothelialisation by harnessing the ultra-structure and chemistry of 
biological scaffolds to facilitate migration of essential cell groups, while maintaining their mechanical 
characteristics.  The complex interaction between these different cell populations, the extracellular 
milieu they are exposed to, and various host factors such as flow dynamics and the immune response, 
are the main determinants of the long-term patency of these vascular conduits.  Elucidating the 
intricate nature of these interactions and attempting to modify these processes is the subject of 
ongoing study in this field.        
 
7. AIMS AND OBJECTIVES 
The aim of this study is to assess the clinical feasibility of decellularised vascular grafts, which have 
been produced by utilising protocols based on earlier work, using an established large animal model.  
The objectives of the study include: 
• determination of the rate of patency of the vascular grafts in a large animal model compared to 
ePTFE grafts as control  
• assessment of the extent of host cellular infiltration of the graft material, including the degree of 
endothelialisation of the luminal surface of the graft 
















1.  Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of 
Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33 Suppl 1(1):S1-75. 
doi:10.1016/j.ejvs.2006.09.024 
2.  Onen CL. Epidemiology of ischaemic heart disease in sub-Saharan Africa. Cardiovasc J Afr. 
2013;24(2):34-42. doi:10.5830/CVJA-2012-071 
3.  Moran A, Forouzanfar M, Sampson U, et al. The Epidemiology of Cardiovascular Diseases in 
Sub-Saharan Africa: The Global Burden of Diseases, Injuries and Risk Factors 2010 Study. Prog 
Cardiovasc Dis. 2013;56(3):234-239. doi:10.1016/j.micinf.2011.07.011.Innate 
4.  Klinkert P, Post PN, Breslau PJ, et al. Saphenous vein versus PTFE for above-knee 
femoropopliteal bypass. A review of the literature. Eur J Vasc Endovasc Surg. 2004;27(4):357-
362. doi:10.1016/j.ejvs.2003.12.027 
5.  Darouiche RO. Treatment of infections associated with surgical implants. N Engl J Med. 
2004;350(14):1422-1429. doi:10.1056/NEJMra035415 
6.  Veith FJ, Gupta SK, Ascer E, et al. Six-year prospective multicenter randomized comparison of 
autologous saphenous vein and expanded polytetrafluoroethylene grafts in infrainguinal 
arterial reconstructions. J Vasc Surg. 1986;3(1):104-114. 
7.  Neville RF, Capone A, Amdur R, et al. A comparison of tibial artery bypass performed with 
heparin-bonded expanded polytetrafluoroethylene and great saphenous vein to treat critical 
limb ischemia. J Vasc Surg. 2012;56(4):1008-1014. doi:10.1016/j.jvs.2012.03.020 
8.  Lösel-Sadée H, Alefelder C. Heparin-bonded expanded polytetrafluoroethylene graft for 
infragenicular bypass: five-year results. J Cardiovasc Surg (Torino). 2009;50(3):339-343. 
9.  Khalil A a M, Griffiths G, Boyd A. Interposition vein cuff for infragenicular prosthetic bypass 
graft. Cochrane Database Syst Rev. 2012;12(9). doi:10.1002/14651858.CD007921 
10.  Ziegler K, Muto A, Eghbalieh S, et al. Basic Data Related to Operative Infrainguinal 
Revascularization Procedures: A Twenty Year Update. Ann Vasc Surg. 2012;25(3):413-422. 
doi:10.1016/j.avsg.2010.10.010.Basic 
11.  Veith FJ, Moss CM, Sprayregen S, et al. Preoperative saphenous venography in arterial 
reconstructive surgery of the lower extremity. Surgery. 1979;85(3):253-256. 
12.  van Hinsbergh VWM. Endothelium--role in regulation of coagulation and inflammation. Semin 
Immunopathol. 2012;34(1):93-106. doi:10.1007/s00281-011-0285-5 
13.  Byrom MJ, Bannon PG, White GH, et al. Animal models for the assessment of novel vascular 
Stabilised Decellularised Vascular Grafts in an Ovine Carotid Model – Literature Review 
 15 
conduits. J Vasc Surg. 2010;52(1):176-195. doi:10.1016/j.jvs.2009.10.080 
14.  Davis L, Dower T, Zilla P. The lack of healing in conventional vascular grafts. In: Zilla P, Greisler 
H, eds. Tissue Engineering of Vascular Prosthetic Grafts. Landes Company: Austin, TX, USA; 
1999:3-44. 
15.  Greisler H. Characteristics and healing of vascular grafts. In: Callow A, Ernst C, eds. Vascular 
Surgery: Theory and Practice. Appleton & Lange: Stamford (Conn), New York; 1995:1181-
1212. 
16.  Zilla P, Bezuidenhout D, Human P. Prosthetic vascular grafts: wrong models, wrong questions 
and no healing. Biomaterials. 2007;28(34):5009-5027. 
doi:10.1016/j.biomaterials.2007.07.017 
17.  Salacinski HJ, Goldner S, Giudiceandrea A, et al. The mechanical behavior of vascular grafts: a 
review. J Biomater Appl. 2001;15(3):241-278. doi:10.1106/NA5T-J57A-JTDD-FD04 
18.  Pellegata AF, Asnaghi MA, Stefani I, et al. Detergent-enzymatic decellularization of swine 
blood vessels: insight on mechanical properties for vascular tissue engineering. Biomed Res 
Int. 2013;2013:918753. doi:10.1155/2013/918753 
19.  Haruguchi H, Teraoka S. Intimal hyperplasia and hemodynamic factors in arterial bypass and 
arteriovenous grafts: A review. J Artif Organs. 2003;6(4):227-235. doi:10.1007/s10047-003-
0232-x 
20.  Sarkar S, Salacinski HJ, Hamilton G, et al. The mechanical properties of infrainguinal vascular 
bypass grafts: their role in influencing patency. Eur J Vasc Endovasc Surg. 2006;31(6):627-636. 
doi:10.1016/j.ejvs.2006.01.006 
21.  Prichard HL, Manson RJ, DiBernardo L, et al. An early study on the mechanisms that allow 
tissue-engineered vascular grafts to resist intimal hyperplasia. J Cardiovasc Transl Res. 
2011;4(5):674-682. doi:10.1007/s12265-011-9306-y 
22.  Li S, Sengupta D, Chien S. Vascular tissue engineering: from in vitro to in situ. Wiley Interdiscip 
Rev Syst Biol Med. 2014;6(1):61-76. doi:10.1002/wsbm.1246 
23.  Bergmeister H, Strobl M, Grasl C, et al. Tissue engineering of vascular grafts. Eur Surg. 
2013;45(4):187-193. doi:10.1007/s10353-013-0224-x 
24.  Catto V, Farè S, Freddi G, et al. Vascular Tissue Engineering: Recent Advances in Small 
Diameter Blood Vessel Regeneration. ISRN Vasc Med. 2014;2014:1-27. 
doi:10.1155/2014/923030 
25.  Deutsch M, Meinhart J, Zilla P, et al. Long-term experience in autologous in vitro 
endothelialization of infrainguinal ePTFE grafts. J Vasc Surg. 2009;49(2):352-362. 
doi:10.1016/j.jvs.2008.08.101 
Stabilised Decellularised Vascular Grafts in an Ovine Carotid Model – Literature Review 
 16 
26.  Chong DST, Lindsey B, Dalby MJ, et al. Luminal surface engineering, “micro and 
nanopatterning”: potential for self endothelialising vascular grafts? Eur J Vasc Endovasc Surg. 
2014;47(5):566-576. doi:10.1016/j.ejvs.2014.02.007 
27.  Piterina A V, Cloonan AJ, Meaney CL, et al. ECM-based materials in cardiovascular 
applications: Inherent healing potential and augmentation of native regenerative processes. 
Int J Mol Sci. 2009;10(10):4375-4417. doi:10.3390/ijms10104375 
28.  Williams C, Liao J, Joyce E, et al. Altered structural and mechanical properties in 
decellularized rabbit carotid arteries. Acta Biomater. 2009;5(4):993-1005. 
doi:10.1016/j.actbio.2008.11.028.Altered 
29.  Paxton S, Peckham M, Adele K. The Leeds Histology Guide. 
http://www.histology.leeds.ac.uk/circulatory/arteries.php. Published 2003. Accessed May 11, 
2017. 
30.  Bashir MM, Indik Z, Yeh H, et al. Characterization of the complete human elastin gene. 
Delineation of unusual features in the 5’-flanking region. J Biol Chem. 1989;264(15):8887-
8891. 
31.  Shapiro SD, Endicott SK, Province MA, et al. Marked longevity of human lung parenchymal 
elastic fibers deduced from prevalence of D-aspartate and nuclear weapons-related 
radiocarbon. J Clin Invest. 1991;87(5):1828-1834. doi:10.1172/JCI115204 
32.  Robert L, Hornebeck W. Elastin and Elastases, Volume 2. CRC Press; 1989. 
33.  Cecelja M, Chowienczyk P. Molecular Mechanisms of Arterial Stiffening. Pulse (Basel, 
Switzerland). 2016;4(1):43-48. doi:10.1159/000446399 
34.  Basalyga DM, Simionescu DT, Xiong W, et al. Elastin degradation and calcification in an 
abdominal aorta injury model: role of matrix metalloproteinases. Circulation. 
2004;110(22):3480-3487. doi:10.1161/01.CIR.0000148367.08413.E9 
35.  Bailey M, Xiao H, Ogle M, et al. Aluminum chloride pretreatment of elastin inhibits elastolysis 
by matrix metalloproteinases and leads to inhibition of elastin-oriented calcification. Am J 
Pathol. 2001;159(6):1981-1986. doi:10.1016/S0002-9440(10)63048-9 
36.  Isenburg JC, Simionescu DT, Vyavahare NR. Elastin stabilization in cardiovascular implants: 
improved resistance to enzymatic degradation by treatment with tannic acid. Biomaterials. 
2004;25(16):3293-3302. doi:10.1016/j.biomaterials.2003.10.001 
37.  Chuang T-H, Stabler C, Simionescu A, et al. Polyphenol-Stabilized Tubular Elastin Scaffolds for 
Tissue Engineered Vascular Grafts. Tissue Eng Part A. 2009;15(10):2837-2851. 
doi:10.1089/ten.TEA.2008.0394 
38.  Isenburg JC, Simionescu DT, Starcher BC, et al. Elastin stabilization for treatment of 
Stabilised Decellularised Vascular Grafts in an Ovine Carotid Model – Literature Review 
 17 
abdominal aortic aneurysms. Circulation. 2007;115(13):1729-1737. 
doi:10.1161/CIRCULATIONAHA.106.672873 
39.  Minor RR. Collagen metabolism: a comparison of diseases of collagen and diseases affecting 
collagen. Am J Pathol. 1980;98(1):225-280. 
40.  Liao D, Wang X, Lin PH, et al. Covalent linkage of heparin provides a stable anti-coagulation 
surface of decellularized porcine arteries. J Cell Mol Med. 2009;13(8 B):2736-2743. 
doi:10.1111/j.1582-4934.2008.00589.x 
41.  Raghunath K, Biswas G, Panduranga Rao K, et al. Some characteristics of collagen-heparin 
complex. J Biomed Mater Res. 1983;17(4):613-621. doi:10.1002/jbm.820170406 
42.  Pennel T, Fercana G, Bezuidenhout D, et al. The performance of cross-linked acellular arterial 
scaffolds as vascular grafts; pre-clinical testing in direct and isolation loop circulatory models. 
Biomaterials. 2014;35(24):6311-6322. doi:10.1016/j.biomaterials.2014.04.062 
43.  Bezuidenhout D, Davies N, Black M, et al. Covalent surface heparinization potentiates porous 
polyurethane scaffold vascularization. J Biomater Appl. 2010;24(5):401-418. 
doi:10.1177/0885328208097565 
44.  van der Lei B, Robinson PH, Bartels HL, et al. Microarterial grafting into the carotid artery of 
the rabbit: some considerations concerning species-dependent thrombogenicity. Br J Plast 
Surg. 1989;42(1):59-64. 
45.  Desai M, Seifalian AM, Hamilton G. Role of prosthetic conduits in coronary artery bypass 
grafting. Eur J Cardiothorac Surg. 2011;40(2):394-398. doi:10.1016/j.ejcts.2010.11.050 
46.  Abbott WM, Callow A, Moore W, et al. Evaluation and performance standards for arterial 
prostheses. J Vasc Surg. 1993;17(4):746-756. 
47.  Swartz DD, Andreadis ST. Animal models for vascular tissue-engineering. Curr Opin 
Biotechnol. 2013;24(5):916-925. doi:10.1016/j.copbio.2013.05.005 
48.  Konya A, Wright K, Gounis M, et al. Animal models for atherosclerosis, restenosis, and 
endovascular aneurysm repair. In: Conn P, ed. Sourcebook of Models for Biomedical Research. 
NJ: Humana Press; 2008:369-384. 
49.  Blunt MH. Cellular Elements of Ovine Blood. In: Blunt MH, ed. The Blood of Sheep: 
Composition and Function. Berlin, Heidelberg: Springer Berlin Heidelberg; 1975:29-44. 
doi:10.1007/978-3-642-66115-0_2 
50.  Didisheim P. Comparative hematology in the human, calf, sheep and goat. Relevance to 
implantable blood pump evaluation. ASAIO J. 1985;8(3):123-127. 
51.  Tillman P, Carson SN, Talken L. Platelet function and coagulation parameters in sheep during 
experimental vascular surgery. Lab Anim Sci. 1981;31(3):263-267. 
Stabilised Decellularised Vascular Grafts in an Ovine Carotid Model – Literature Review 
 18 
52.  Connell JM, Khalapyan T, Al-Mondhiry H a, et al. Anticoagulation of juvenile sheep and goats 
with heparin, warfarin, and clopidogrel. ASAIO J. 2007;53(2):229-237. 
doi:10.1097/MAT.0b013e31802e192b 
53.  Weigand A, Boos AM, Ringwald J, et al. New aspects on efficient anticoagulation and 
antiplatelet strategies in sheep. BMC Vet Res. 2013;9:192. doi:10.1186/1746-6148-9-192 
54.  Baldwin BA, Bell FR. The effect on blood pressure in the sheep and calf of clamping some of 
the arteries contributing to the cephalic circulation. J Physiol. 1963;167(3):463-479. 
55.  May ND. Experimental studies of the collateral circulation in the head and neck of sheep 
(Ovis aries). J Anat. 1968;103(Pt 1):171-181. 
56.  Kaushal S, Amiel G, Guleserian K. Functional Small Diameter Neovessels using Endothelial 
Progenitor Cells Expanded Ex Vivo. Nat Med. 2001;7(9):1035-1040. doi:10.1038/nm0901-
1035.Functional 
57.  Tillman BW, Yazdani SK, Neff LP, et al. Bioengineered vascular access maintains structural 
integrity in response to arteriovenous flow and repeated needle puncture. J Vasc Surg. 
2012;56(3):783-793. doi:10.1016/j.jvs.2012.02.030 
58.  Pavcnik D, Obermiller J, Uchida BT, et al. Angiographic evaluation of carotid artery grafting 
with prefabricated small-diameter, small-intestinal submucosa grafts in sheep. Cardiovasc 
Intervent Radiol. 2009;32(1):106-113. doi:10.1007/s00270-008-9449-7 
59.  Bergmeister H, Boeck P, Kasimir M-T, et al. Effect of laser perforation on the remodeling of 
acellular matrix grafts. J Biomed Mater Res B Appl Biomater. 2005;74(1):495-503. 
doi:10.1002/jbm.b.30228 
60.  Sardelic F, Fletcher JP, Ao PY, et al. Comparison of fluoropolymer passivated Dacron and 
polytetrafluoroethylene grafts in a sheep model. Cardiovascular surgery (London, England). 
http://www.ncbi.nlm.nih.gov/pubmed/8049954. Published 1994. Accessed July 23, 2015. 
61.  Pedersen G, Laxdal E, Ellensen V, et al. Improved patency and reduced intimal hyperplasia in 
PTFE grafts with luminal immobilized heparin compared with standard PTFE grafts at six 
months in a sheep model. J Cardiovasc Surg (Torino). 2010;51(3):443-448. 
62.  Baek I, Bai CZ, Hwang J, et al. Paclitaxel coating of the luminal surface of hemodialysis grafts 














Stabilised Decellularised Vascular Grafts in an Ovine Carotid Model – Manuscript 
 
             20 
1. INTRODUCTION 
There is significant morbidity and mortality associated with cardiovascular disease, which exert a 
major burden on healthcare systems worldwide.  The worldwide increase in the co-morbid illnesses 
of diabetes, hypertension and dyslipidaemia have resulted in an increase in the prevalence of coronary 
artery and peripheral vascular disease.1,2  With more populations in the developing world adopting a 
western lifestyle and diet, there is also an expected increase in these illnesses in Africa.3 
 
When medical and endovascular therapeutic modalities fail, surgical bypass of the diseased segment 
of artery is required.  For larger arteries, synthetic vascular grafts such as polytetrafluoroethylene 
(ePTFE) and polyethylene terephthalate (Dacron) offer viable curative options and have good long-
term patency rates.  However, for smaller vessel disease, such as in below-knee bypass, patency rates 
are unacceptably low.4  An autologous vein graft, usually involving harvest of the saphenous vein, is 
required in these clinical situations.  However, due to anatomic variation or disease, this is not 
available in one third of patients.5 
 
The primary causative factors that result in graft occlusion are a lack of endothelium, and mechanical 
mismatch between the native artery and graft.  The endothelium plays a central role in regulating 
thrombosis and thus much of the current study into alternative vascular grafts aims to achieve 
endothelialisation of the luminal surface of these grafts.6  Calibre and compliance mismatch cause 
abnormalities of flow, which stimulate a smooth muscle cell mediated deposition of extracellular 
matrix at sites of anastomosis.7  The progressive narrowing eventually results in thrombosis and 
occlusion. 
 
Various tissue engineering approaches have been adopted to address these two problems.  In-vitro 
endothelisation utilizing endothelial cell culture and complex bioreactor systems have demonstrated 
the best results,8 but are resource intensive and require long lead times to produce, and are thus not 
suitable for large-scale production.9  Consequently, the focus has shifted toward in-situ 
endothelialisation of animal-derived decellularised vascular grafts.  The extracellular matrix (ECM) of 
these grafts have similar mechanical characteristics to native arteries10 and possess the cell signalling 
proteins that could facilitate endothelial cell migration.  In producing decellularised grafts, a balance 
is sought between effectively removing all antigenic material while maintaining the mechanical and 
chemical integrity of the ECM.  There is significant variation in the mechanical properties between 
grafts produced with different decellularisation protocols,11,12 highlighting the importance of refining 
the process used to produce these grafts.  
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Collagen and elastin, the ECM proteins which confer strength and distensibility to arteries, are prone 
to degradation by both the decellularisation process and by host proteases.  Our group previously 
described the use of penta-galloyl glucose (PGG), a polyphenolic tannin, to reduce the degradation of 
elastin.13,14  PGG treatment of decellularised porcine arteries demonstrated strong resistance to 
elastase and similar mechanical properties to fresh native arteries.  Collagen stabilisation was 
achieved as an added effect of the heparinisation process.  Using Jeffamine (a diamine) heparin was 
covalently bound to collagen and cross-links between collagen molecules were formed.15  This method 
also achieves significantly higher heparin content compared to passive soaking in heparin solutions15,16 
and does not reduce its anticoagulant effects.17   
 
The viability and efficacy of this decellularisation and stabilisation protocol was tested in a small 
animal model by utilising it to prepare harvested porcine renal arteries for implantation into rat aortas 
as isolation loop implants. Compared to untreated grafts, the stabilised grafts demonstrated higher 
patency and reduced elastin degeneration, effectively preventing aneurysmal dilatation.15   
 
Having demonstrated the biological safety and viability of this graft preparation protocol, a large 
animal study was undertaken to more closely simulate human vascular flow dynamics and 
haematological physiology. The ovine carotid model best fulfils the requirements to test conduits 
intended for use in below-knee and coronary bypass (4-6mm).  The diametric size of the sheep 
common carotid artery closely matches that of the test conduits and is of sufficient length.18  
Additionally, ePTFE within this size range implanted in sheep has been shown to have patency rates 
similar to that seen in humans.19  
 
By harnessing their mechanical and chemical properties, it is hypothesised that the stabilised 
decellularised grafts will both facilitate endothelialisation and reduce intimal hyperplasia, thereby 
improving patency rates.  By comparing the current clinical standard (ePTFE) with the tested graft 
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2. METHODS 
2.1. Harvesting and decellularisation 
Fresh porcine mammary arteries were sourced from Animal Technologies© (Inc.) and received on ice 
by our collaborators. The fresh arteries were cleared of excess tissue and checked for leaks from side 
branches, which were ligated with 3-0 braided polyethylene suture.  The samples were treated 
overnight in 30 mM ethylenediaminetetraacetic acid (EDTA) and 0.02% sodium azide (NaN3) on an 
orbital shaker at 3.5 rpm at 4°C.   
 
The prepared specimens were decellularised by our collaborators in a bioprocessing protocol 
previously designed and validated by them.20  Briefly, the arteries were mounted in a perfusion 
bioreactor, which facilitates treatment of the outer and luminal surfaces of the graft under pressure. 
Using this perfusion system, the arteries were first rinsed with double distilled water (ddH2O).   The 
detergent sodium dodecyl sulfate (SDS) was used as the primary cell lysing agent.  The grafts were 
incubated for 12 days in 1% SDS solution.  Following rinsing of the SDS with ddH2O, the grafts were 
treated with 70% ethanol (EtOH) for 3 hours and sodium hydroxide (NaOH) for 2 hours.  Overnight 
treatment with phosphate buffered saline (PBS) was followed by 96 hours of enzymatic treatment 
with DNAse and RNAse (720munits/ml).  Sterilisation of the grafts was achieved with peracetic acid. 
 
2.2. Elastin stabilization with penta-galloyl glucose 
Following decellularisation and sterilization, the grafts were soaked in 0.15% penta-galloyl glucose 
(PGG, N.V. Ajinomoto OmniChem S.A., Wetteren, Belgium) in 50 mM dibasic sodium phosphate buffer 
with 20% isopropanol in saline (pH 5.5) for 24 hours. The grafts then underwent a 6-day rinse with 
ddH2O and PBS, and stored in sterile PBS + 1% antimicrobial solution (antibiotic and antifungal) for 
shipping to Cape Town, South Africa. 
 
2.3. Heparinisation  
The heparinisation process was conducted by our group and was achieved with 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide(EDC) / N-Hydroxysuccinimide(NHS) activated Jeffamineâ (D-230 
polyoxypropylenediamine) coupling prior to heparinisation. 
 
The decellularised grafts were first pre-soaked in 240mM Jeffamine solution for 30 minutes to 
infiltrate the tissue with excess Jeffamine.  Samples were then immersed in a combination of 
Jeffamine/EDC/NHS solution (2.3g EDC and 0.56g NHS per 50mls 240mM Jeffamine solution) for two 
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and half hours. Following a PBS rinse, nitrous acid degraded heparin (Celsus Glycoscience, Inc) was 
combined in solution with the reducing agent sodium cyanoborohydride (NaCNBH3, 2mg/ml) and used 
to treat the samples for 18 hours.  The samples were then rinsed with PBS and normal saline, and 
stored individually in PBS-filled tubes.  
 
2.4. Heparin content assessment 
A heparinised graft and untreated graft (as control) were excluded from in-vitro testing and utilised to 
assess heparin content.  Three specimens were sampled from the untreated graft, and three each 
from the mid-section and end of the heparinised graft (i.e. 6 heparinised samples).  The specimens 
were subjected to a colorimetric procedure as previously described16 from a modified technique 
developed by Riesenfeld and Roden.21  Briefly, the samples were treated with deionized water (DI) 
and nitrous acid solution (0.025M HNO2, 0.9M HCl), which selectively cleaves N-sulfated glucosamine 
residues from heparin. These residues are reacted with 3-methyl-2- benzothiazoninone hydrazone 
(MBTH) solution, which is then complexed with FeCl3 (500 mL of an 0.031M solution, 50C, 20 min).  
The absorbance of the resultant solution is determined by UV spectroscopy (660nm, ShimadzuUV-
1601PC) and the heparin content of the sample (mg/g of tissue) thus determined from standard 
curves.  To assess the degree of loss of heparin content during storage, the assessment was repeated 
on a similar set of specimens sampled from grafts held in cold-storage (4o C) for 11 weeks.  
 
2.5. Mechanical properties  
Pre-heparinisation and post-heparinisation grafts were selected for mechanical testing using an 
Instron® 5544 load frame (Illinois Tool Works Inc.) strain extensometer.  For circumferential tensile 
strength testing, 1cm samples were applied to the machine attachments and extended at 1mm/sec 
to failure.  The rate of stretch and force required were recorded and used to derive stress-strain 
curves. 
 
Suture retention strength was assessed by passing size 4/0 braided suture through the graft at 1mm 
from the graft edge and fixing the graft and the looped suture to the machine attachments and 
similarly extended to failure.  The procedure was repeated at 3 separate points on the same test graft 
edge to assess for consistency of mechanical properties. 
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2.6. Implant procedure 
Six adult female Merino sheep weighing 75-80kg were used for the experiments.  The protocol of 
animal experiments and care was approved by the Animal Ethics Committee of the University of Cape 
Town (Ethics No: 013/023). 
 
Pre-operative preparation included a 12-hour fasting period, antibiotic prophylaxis (Cefotaxime 1g IM) 
and analgesia (Buprenorphine 0.01mg/kg).  Induction of anaesthesia was established with 
Medetomidine (25μg/kg IM) and Ketamine (1mg/kg), and maintained with Isoflurane (2- 3%) in 
oxygen and nitrous oxide.  
 
Sterile technique was maintained throughout the procedure.  The common carotid artery was exposed 
on both sides via bilateral 10-12cm incisions made in the mid-neck.  Heparin (5000iu IV) was 
administered prior to arterial cross-clamping.  A 5cm section of common carotid artery was excised 
and the grafts were implanted as carotid interposition grafts using 6/0 polypropylene sutures 
(Proleneâ, Ethicon).  ePTFE (6mm, GORE-TEX®, Gore) was implanted on the left side as a control and 
the decellularised grafts implanted on the right side.   
 
Enoxaparin (Clexaneâ 80mg sub-cutaneous, Sanofi-Aventis) was administered daily for 1 week 
following implantation and Clopidogrel (Plavixâ 75mg orally, Sanofi-Aventis) was given for the full 
implant period.  After an average implant period of two months the grafts were assessed for patency 
using ultrasound and angiography.  The grafts were then explanted under general anaesthesia and the 
animal euthanized. 
 
2.7. Assessment of patency 
Patency was assessed prior to explantation with duplex doppler ultrasound (US), on angiogram and 
post-explantation by macroscopic assessment. Samples from animals euthanised before the end-
point were excluded from the analysis.   
 
US assessment was performed by a registered ultrasonographer who specialises in human carotid 
artery assessment.  Anastomotic sites were assessed for intimal hyperplasia using B-mode US and the 
presence and velocity of flow with Doppler-mode US. 
 
Angiography was performed by the operating surgeon with the animal anaesthetised just prior to 
explant.  The femoral artery (left or right) was accessed percutaneously under US guidance and the 
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angiogram catheter positioned using the seldinger (over-guidewire) technique at the root of the aorta 
under X-ray guidance.  IV contrast (Iohexol 300mg/ml, OmnipaqueÔ)  was injected and X-Ray 
screening of the neck was taken to assess the presence of contrast in both common carotid arteries.   
 
Direct macroscopic assessment of patency was done by palpation of the surgically exposed grafts.  
Following resection of the grafts, injection of saline through the grafts was attempted to assess 
patency. 
 
2.8. Specimen preparation & histological analysis 
The explanted grafts were fixed in formalin solution for 24 hours before being embedded in paraffin. 
Sections were cut longitudinally and dewaxed with 2,2,4-trimethylpentane. Haematoxylin (Merck, 
Damstadt, Germany) and eosin (BDH; WWR International, Poole, England) (H&E), Miller and Masson 
elastin trichrome stain Willebrand (Dako, AS, Glostrup, Denmark). Histology analysis was performed 
with a Nikon eclipse 90i microscope (Nikon, Tokyo, Japan) at 4x, 10x and 40x magnification. 
 
2.9. Statistical analysis 
Statistical tests were performed with STATA (StataCorp. 2013. Stata Statistical Software: 
Release 13.0 College Station, TX: StataCorp LP).  Results were expressed as mean ± standard deviation 
(SD).  Significant differences between means were determined by Student's t- test (paired, two-tailed) 
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Table 1  
Graft dimensions 
3. RESULTS 
3.1. Decellularised graft dimensions & handling 
Acquiring animal derived grafts of suitable dimensions proved to be challenging.  The harvested grafts 
were more than 50% larger than expected and the mean tapering ratio (ratio of diameter at proximal 
end to diameter at distal end) was 48% (Figure 1 & Table 1).  This calibre mismatch between the test 
graft and the native sheep carotid artery resulted in difficulties in constructing the anastomosis, which 
necessitated altering the surgical technique by spatulating either the graft or the native artery.  This 







The decellularised grafts had good surgical handling which was judged by the surgeon to be superior 
to that of the ePTFE grafts.  Needle passage was smooth, and the graft edge held the suture material 
well.  The graft demonstrated good shape memory, maintaining its cylindrical shape and after being 
compressed with digital pressure, returned to its original shape, albeit more slowly than ePTFE.  While 
the graft length of ePTFE could be doubled with longitudinal traction, the decellularised graft had 
minimal capacity for expansion (Figure 2). The anastomotic line of the test graft formed a good seal 
with the native artery with minimal extravasation of blood once flow was re-established, comparable 










Proximal  Mid  Distal  
1 63 11 8 10 
2 98 11 8 5 
3 123 8 8 6.5 
4 139 9 7.5 6 
5 124 5 5 5 
6 100 10 9 6.5 
7 112 11.5 8 6.5 
Figure 1: Decellularised grafts showing heterogeneity 
of dimensions  
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Sheep 1 - Left 
Sheep 2 - Left 
Sheep 3 - Left 
Sheep 4 - Left 
Sheep 5 - Left 
Sheep 1 – Right 
Sheep 2 - Right 
Sheep 3 - Right 
Sheep 4 - Right 
Sheep 5 - Right 
Sheep 6 - Left Sheep 6 - Right 
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3.2. Heparin content 
The control grafts had negligible heparin content (mean 0.69 ±0.12mg/g of tissue).   
 
The mean heparin content of the treated grafts (3 end- and 3 mid-section specimens) shortly after the 
heparinisation process was completed (0 weeks) was 14.56 ±4.01mg/g.   After 11 weeks of cold 
storage of these grafts in PBS solution, the mean heparin content had not decreased significantly 
(14.56 ±4.01mg/g vs 13.41 ±3.88mg/g, NS).  
 
There was a significant difference of heparin content between mid- and end-sections of the graft at 
both 0 weeks (11.03 ±0.33mg/g vs 18.08 ±1.72mg/g, p = 0.002) and after 11 weeks of cold storage 
























Figure 3: Heparin content after covalent cross-linking with 
Jeffamine demonstrating a significant difference in heparin 
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3.3. Mechanical properties 
The maximum circumferential load tolerated by the unheparinised graft sample before breaking was 
43.79N compared to 47.54N for the heparin-treated sample.  The heparinised sample was slightly 
larger than the untreated sample (surface area 24.54mm2 vs 21.71mm2) and when taking these 
dimensions into account, the derived ultimate strength of the heparin-treated sample was similar to 
that of the untreated sample (1.9MPa vs 2.0MPa).  The stress-strain curves (Figure 4) of the two 
samples were also similar, demonstrating little change in stiffness after heparinisation. 
 
Suture pull-out test results were also similar between heparinised and control specimens.  The mean 























Figure 4 – Comparison of stress-strain relationships of the heparin–
treated and untreated (control) decellularised graft samples 
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All five of the decellularised grafts were occluded (0% patency) while 2 out of 5 ePTFE grafts remained 









The ultrasound assessment of each of the test grafts demonstrated complete occlusion at both the 








Sheep Right (Decel) Left (ePTFE) 
1 Occluded Patent 
2 Euthanised Day 4 post-operative (Sepsis) 
3 Occluded Occluded 
4 Occluded Patent 
5 Occluded Occluded 





Figure 5 – In-situ US image demonstrating a: the interface of the native artery and the 
decellularised graft. Significant stenosis is seen at the site of anastomosis. In contrast, b: 
demonstrates the patent ePTFE graft. 
ePTFE anastomosis Native 
artery 
ba
Stabilised Decellularised Vascular Grafts in an Ovine Carotid Model – Manuscript 
 
             31 
3.5. Macroscopic appearance 
ePTFE grafts demonstrated familiar post-explant characteristics with minimal surrounding fibrosis and 
dissection from adjacent tissues with relative ease.  No neo-intimal reaction was found within the 
lumen of the patent grafts (Figure 6a).  In contrast, the decellularised grafts were encased in dense 
fibrotic tissue which was difficult to separate from surrounding tissues. No ectasia or aneurysmal 
deformation was noted in any of the decellularised grafts. The lumen of all grafts were occluded by 
concentric organised thrombus (Fig 6b).  Longitudinal section demonstrated stricture at the sites of 



























Figure 6: External and luminal appearance of ePTFE and decellularised graft from the same 
animal. a: ePTFE graft demonstrating patent lumen. b: Decellularised graft with perigraft & 
luminal neointimal hyperplasia. c: Longitudinal section of decellularised graft and d: 
demonstrating anastomotic stricture. 
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3.6. Microscopic appearance 
Histological analysis of the control group were typical for ePTFE, with pannus ingrowth from the 
adjacent anastomosis (Figure 7, a&b). A single layer of flat nucleated cells lined the surface of the 
pannus and extended a short distance onto the luminal surface of the ePTFE representing 
transanastomotic endothelial ingrowth (Figure 7, e) with the luminal mid-graft remaining acellular. 
Perigraft foreign body response was limited to a few mononuclear inflammatory cells (Figure 7, f) with 
minimal cellular ingrowth into the abluminal surface of the graft (Figure 7, c&d). 
Due to the complete occlusion of the decellularized grafts, only limited comment could be made on 
the extent of luminal healing.  However, minimal pannus ingrowth would suggest that occlusion was 
acute (Figure 7, g&h). The luminal surface remained free of cells, with an exposed internal elastic 
lamina (Figure 7, k) and no abluminal penetration of the grafts with surrounding tissue (Figure 7 i&j) 
resulting in a completely acellular graft (Figure 7 m&n). The surrounding perigraft foreign body 
inflammatory response was more intense than the ePTFE and was macrophage and giant cell 





































a b g h 
c d i j 
e f k l 
m n Figure 7: The histology sequence represent micrographs of H&E (a,c, e-g, i, k-m) and 
Masson trichrome (b,d,h,j,n) stains.  The control ePTFE graft (a-f) and the decellularized 
xenograft (g-n) denote the anastomosis (a,b,g,h; 4x mag), the abluminal (c, d, i, j; 10x 
mag) and the luminal surface (e&k; 10x mag). High-magnification images (40x mag) 
represent the perigaft tissue(f&l) and the mid-graft (m&n). Scale bars: 500µm, 100µm 
& 50µm for 4x, 10x & 40x magnification respectively. 
 







This study aimed to assess the clinical feasibility of chemically stabilised decellularised vascular grafts 
by testing in an ovine carotid model.  None of the test grafts remained patent for the implant period, 
compared to 40% of the ePTFE grafts.  Microscopic analysis revealed thrombosis at the sites of 
anastomosis without intimal hyperplasia and no sign of luminal endothelisation.  The mechanical 
properties were assessed as being favourable, both in terms of surgical handling and by objective load 
testing.     
 
The ovine carotid model used in our experiments provides a robust test of vascular grafts as it is similar 
to human vascular physiology.18  Studies that have employed this model combined with ex-vivo 
preparation have achieved patency rates comparable to autologous vein grafts.  For example, Kaushal 
et al (2001) seeded decellularised porcine iliac arteries (4mm) with endothelial progenitor cells (EPC) 
harvested from juvenile sheep.  Seven of these grafts were implanted as carotid interposition grafts 
and all remained patent beyond 4 months.22  In contrast, groups that do not employ prior ex-vivo 
preparation have reported disappointing results23–27 which are not superior to ePTFE tested under 
similar conditions.19,28,29 For example, in a similar experiment to that conducted in this study, Pavcnik 
et al implanted 6mm grafts composed of hydrated small intestinal mucosa as bilateral carotid 
interpositional grafts.  Only thirty percent of these grafts were patent at 3 months.23  The superior 
results of ex-vivo studies do, however, come at a significant cost.  In the Kaushal study, producing 
sufficient quantities of EPCs took 3-weeks to culture and seeding required a complex bioreactor 
system with pressure pre-conditioning.  Although these techniques produce good results, they are not 
easily scalable and thus not clinically feasible.  To find a clinically relevant solution, our group has 
sought to produce an alternative vascular graft based on in-vivo techniques.  The decellularisation 
protocol that was developed produced excellent patency rates in a small animal model15 but has failed 
to achieve comparable results in this large animal study.  Our results mirror those of similar studies 
and highlight the difficulty of producing decellularised vascular grafts that achieve long-term patency 
under clinically relevant conditions.   
 
Heparinisation of synthetic vascular grafts has been used in an attempt to improve patency but has 
not been shown to significantly improve the patency of ePTFE  grafts.30  Despite this lack of effect in 
synthetic grafts, heparin bonding has been employed in the preparation of various decellularised 
grafts,31 as the anticoagulant effects of heparin bonding on collagen was demonstrated in earlier in-






vitro studies.32 In this study, a Jeffamine-based protocol was utilised to increase the heparin content 
of the decellularised grafts and, compared to passive soaking,  a significant increase in the heparin 
content of the grafts using this protocol was demonstrated.   
 
Using Jeffamine to bond heparin to collagen has the added effect of forming cross-links between 
collagen molecules, thereby increasing its resistance to degradation15.  The importance of reducing 
the degradation of both collagen and elastin, the ECM proteins which confer distensibility and 
strength had been demonstrated in earlier work on other decellularised tissues e.g. cardiac valves. 
33,34 By treating the decellularised grafts with PGG to stabilise elastin, our group previously 
demonstrated decreased aneurysmal dilatation of animal-derived grafts in a small animal model.15 In 
this large animal study, both collagen and elastin stabilisation was achieved by incorporating both 
methods into the decellularisation protocol.   
 
The preservation of elastin and collagen was reflected in the favourable compliance profile 
demonstrated on mechanical testing of the decellularised grafts in this study. Comparing these results 
to similar tests of human arteries is problematic for two reasons.  First, there is limited experimental 
data describing the mechanical properties of human carotid arteries.  In those studies that have 
conducted similar experiments, the cadaver specimens are usually harvested from elderly patients 
and thus the results are confounded by age-related calcification and atherosclerosis.35,36 Second, 
explanted specimens lack the response to luminal pressure conferred by smooth muscle cell activity 
and thus do not accurately reflect in-vivo conditions. The mechanical characteristics of arteries in-vivo 
cannot be determined directly, but can be approximated by measuring the degree of expansion in 
response to luminal pressure during the cardiac cycle.  This technique has employed ultrasound (US)37 
and magnetic resonance imaging (MRI) to assess in-vivo flow dynamics and to measure the mechanical 
response of the arterial wall.  Although there was no significant difference in the ultimate strength 
and compliance profiles of heparinised and control samples, compared to these in-vivo data, the 
decellularised grafts from this study demonstrated favourable mechanical characteristics.  The 
ultimate circumferential tensile strength was well within the range of in-vivo conditions and the 
compliance profile of the decellularised grafts in the physiological range was similar to that derived 
from MRI-based computational models.38  
 
Although the mechanical properties of the test grafts were comparable to human arteries, primary 
patency was not achieved.  Macro- and microscopic analysis revealed that all the decellularised grafts 






developed complete occlusion by thrombus formation without signs of intimal hyperplasia, indicating 
that technical factors played a role in the failure of these grafts.  A profound inflammatory response 
(more pronounced than that seen with the ePTFE grafts) with stricture at the anastomotic sites was 
also noted, which suggests that the immune response to the xenograft could have been a contributing 
factor to early graft occlusion.   Of these factors, compliance mismatch was likely the predominant 
cause for graft failure in this study.  The diameters of the harvested porcine mammary arteries varied 
widely and in a number of the grafts, there was a significant difference in calibre of the proximal and 
distal ends. This led to a calibre mismatch which compromised the quality of the anastomoses.  In 
addition to compliance, calibre mismatch has been showed to be a strong predictor of graft failure for 
both synthetic39 and autologous venous grafts.40 While synthetic grafts can be manufactured to the 
required size, this study found that producing animal-derived decellularised grafts with the 
appropriate dimensions is more difficult, and is an important consideration when assessing these 
grafts as a potential ‘off-the-shelf’ solution.  
 
  







While the factors which determine graft success are numerous and their interactions complex, 
numerous studies have highlighted the pivotal role of the endothelium and the mechanical 
characteristics of alternative vascular grafts in achieving long-term patency. The decellularisation 
process, which aims to remove antigenic material while maintaining the chemical and physical 
integrity of the ECM scaffold, is continually being refined.   
 
This study was unable to achieve primary patency of the porcine-derived decellularised vascular grafts 
in a large animal model.  Although the chemical stabilisation of collagen and elastin preserved the 
mechanical properties of the grafts, thrombotic occlusion occurred early, probably as a result of 
calibre mismatch.    Our findings and those of others suggest that current decellularisation techniques 
are able to preserve the mechanical profile of animal-derived vascular grafts but an effective means 
of facilitating in-vivo endothelisation has yet to be achieved.  Based on the success of experiments 
which utilise complex ex-vivo methods to achieve graft endothelisation, further work should be 
directed toward developing a scalable solution to this problem.  Finally, as our experience has shown 
that procuring animal-derived grafts with appropriate dimensions is problematic, the clinical 
feasibility of utilizing these sources needs to be considered and further characterised.   
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